Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Crystal structure of the T315I mutant of AbI kinase.

Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, Xu Q, Shakespeare W, Dalgarno D, Zhu X.

Chem Biol Drug Des. 2007 Sep;70(3):171-81.

PMID:
17718712
2.

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.

Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A, Moll J.

Cancer Res. 2007 Sep 1;67(17):7987-90.

3.

Inhibitors of ABL and the ABL-T315I mutation.

Noronha G, Cao J, Chow CP, Dneprovskaia E, Fine RM, Hood J, Kang X, Klebansky B, Lohse D, Mak CC, McPherson A, Palanki MS, Pathak VP, Renick J, Soll R, Zeng B.

Curr Top Med Chem. 2008;8(10):905-21.

PMID:
18673174
4.

Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.

Tanaka R, Kimura S.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1387-98. doi: 10.1586/14737140.8.9.1387. Review.

PMID:
18759691
5.

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J.

Cancer Res. 2006 Jan 15;66(2):1007-14.

6.

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE.

Cancer Res. 2006 Jun 1;66(11):5790-7.

7.

C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.

Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, Botta M.

ChemMedChem. 2009 Jan;4(1):118-26. doi: 10.1002/cmdc.200800320.

PMID:
19039816
8.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
9.

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.

Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D.

Blood. 2007 Dec 1;110(12):4005-11. Epub 2007 Sep 4.

10.

Direct binding assay for the detection of type IV allosteric inhibitors of Abl.

Schneider R, Becker C, Simard JR, Getlik M, Bohlke N, Janning P, Rauh D.

J Am Chem Soc. 2012 Jun 6;134(22):9138-41. doi: 10.1021/ja303858w. Epub 2012 May 25.

PMID:
22612329
11.

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P, Cronin CN, McTigue M, Kallioniemi O, Porkka K, Murray BW, Wennerberg K.

Nature. 2015 Mar 5;519(7541):102-5. doi: 10.1038/nature14119. Epub 2015 Feb 9.

PMID:
25686603
12.

Flying under the radar: the new wave of BCR-ABL inhibitors.

Quintás-Cardama A, Kantarjian H, Cortes J.

Nat Rev Drug Discov. 2007 Oct;6(10):834-48. Review.

PMID:
17853901
13.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

14.

Insight into the allosteric inhibition of Abl kinase.

Fallacara AL, Tintori C, Radi M, Schenone S, Botta M.

J Chem Inf Model. 2014 May 27;54(5):1325-38. doi: 10.1021/ci500060k. Epub 2014 May 8.

PMID:
24787133
15.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fendrich G, Strauss A, Zhang J, Gray NS, Adrian F, Warmuth M, Pelle X, Grotzfeld R, Berst F, Marzinzik A, Cowan-Jacob SW, Furet P, Mestan J.

Biochim Biophys Acta. 2010 Mar;1804(3):454-62. doi: 10.1016/j.bbapap.2009.12.009.

PMID:
20152788
16.

Characterization of compound 584, an Abl kinase inhibitor with lasting effects.

Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, Marchesi E, Cleris L, Donella-Deana A, Drueckes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C.

Haematologica. 2008 May;93(5):653-61. doi: 10.3324/haematol.12212. Epub 2008 Mar 26.

17.
18.

New resistance mechanisms for small molecule kinase inhibitors of Abl kinase.

Modugno M.

Drug Discov Today Technol. 2014 Mar;11:5-10. doi: 10.1016/j.ddtec.2013.12.001. Review.

PMID:
24847647
19.

Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

Cheetham GM, Charlton PA, Golec JM, Pollard JR.

Cancer Lett. 2007 Jun 28;251(2):323-9. Epub 2007 Jan 19.

PMID:
17240048
20.

c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).

Nagar B.

J Nutr. 2007 Jun;137(6 Suppl 1):1518S-1523S; discussion 1548S.

Supplemental Content

Support Center